The tone of the muscle is defined as a residual tension in a muscle at rest. It is a continuous and passive partial contraction of the muscles which maintains posture. It is determined by resistance encountered with passive stretching of a muscle or the passive movement of a limb at a joint. Hypotonia is a poor muscle tone resulting in floppiness. It is abnormally decreased resistance encountered with passive movement of the joint. It must be differentiated from weakness, which refers to a decrease in the maximum power a muscle can generate.
Hypotonia may or may not be associated with muscle weakness. Although easily recognizable, it may be challenging for a clinician to determine the underlying cause of hypotonia. There is an extensive list of causes, but approaching the case systematically and obtaining a detailed history and physical examination can help reach a diagnosis. Determining the etiology is crucial for the management and prognostication. Specific treatments are available for some diseases, but in general, treatment comprises providing supportive care with rehabilitation services, nutritional and respiratory support.
Hypotonia is usually present at birth and is frequently diagnosed in early infancy. There are numerous reasons for hypotonia in an infant. It can result from abnormalities in the muscles, neuromuscular junction, or the central and peripheral nervous system. It may also be a presenting feature of certain genetic disorders, metabolic diseases, endocrine problems, and acute or chronic illnesses. In about 50% of the cases of hypotonia, etiology can be determined with a detailed history and physical examination. Central causes include hypoxic encephalopathy, brain anomalies/insults, genetic/chromosomal syndromes, congenital or acquired infections, and disorders of metabolism. Peripheral causes include spinal muscular atrophy, myasthenia gravis, drug/toxin exposure, hereditary neuropathies, muscular dystrophies, congenital/metabolic myopathies, and congenital myotonic dystrophies.
The exact incidence of hypotonia is difficult to determine because it is not a disease itself but a presenting feature of various diseases. The majority of the cases of hypotonia are congenital. Among congenital hypotonias, central pathology accounts for most. These typically include hypoxic-ischemic encephalopathy or genetic abnormalities. Central hypotonia is seen in up to 60%-80% of cases. Down syndrome is the most common genetic cause of central hypotonia, followed by Prader Willi syndrome. Metabolic diseases, including peroxisomal and storage disorders, are rare causes of central hypotonia.
Peripheral and unknown causes account for the rest. The most commonly seen peripheral causes include spinal muscle atrophy, congenital muscular dystrophy, and congenital myopathies. Spinal muscular atrophy has an incidence of 1 in 6,000 to 1 in 10,000 live births. Acquired hypotonias can be due to toxins or infections, including infant botulism. Even though worldwide incidence is rare, the majority of cases are diagnosed in the USA, which can be attributed to clinician awareness. In the USA, California, Pennsylvania, and Utah have a high incidence of infant botulism, with about 50% of cases in California.
History - Initial evaluation starts with a detailed history, which should include family history, prenatal, and perinatal history. The developmental history of the child, as well as of the parents, can also aid in the diagnosis. Attention should also be paid to the presence of hypotonia in the family members with a known cause such as muscular diseases, genetic disorders, and consanguineous marriage. Prenatal and perinatal history includes details about the fetal movements, presentation at birth, amniotic fluid amount through the course of pregnancy, and complications during delivery. Details regarding maternal exposure to toxin/drugs, any infections during pregnancy, mode of delivery, gestational age, and Apgar score at birth must also be obtained. Information regarding the onset of hypotonia and the clinical course can also help to determine the etiology. For example, hypotonia at birth with poor Apgar score may indicate hypoxic-ischemic encephalopathy, whereas poor muscle tone developing 12 - 24 hours after birth may indicate a metabolic disorder. Infants with central hypotonia usually have a higher prevalence of cognitive delays. A standardized neurodevelopmental assessment must be done in older children. The Bayley scale (Bayley -III) may be used. It covers the ages from 1 to 42 months and assesses motor, cognitive, language, and social-emotional domains of development. However, the assessment with Bayley - III or any other standardized scale may be difficult when the infant has a profound weakness. A careful review of all organ systems must be included as well as it may aid in the diagnosis of the underlying etiology.
Physical examination - A detailed physical examination, along with a comprehensive neurologic examination, must be done. Paying attention to dysmorphic features or any associated congenital malformations. The shape and size of the head must be included as well. Muscular strength should be evaluated in a child with hypotonia. It should also be determined if the hypotonia has progressed since onset or has remained static. The infant's tone can be assessed by using 4 maneuvers. 1) Vertical suspension, 2) Horizontal suspension, 3) "The Scarf Sign," and 4) "Pull to sit" maneuver.
It is usually challenging to determine muscle strength in an infant. Weakness may be manifest as decreased spontaneous movements. This can be tested by evaluating the cry, suck reflex, spontaneous movements, facial expressions, antigravity movements, and respiratory effort. When assessing weakness in an infant, the course and area of involvement must be noted as well. These findings may be confounded in the setting of a severe systemic illness (e.g., sepsis), or medications (e.g., magnesium or sedatives). This can be overcome by examining the patient on 2 separate occasions.
Patients with central hypotonia usually have a depressed level of consciousness, normal muscle strength, reflexes may be normal or exaggerated, and the persistence of primitive reflex and clonus. They may also have dysmorphic features and congenital abnormalities, pointing towards a syndromic cause of hypotonia. These findings vary in severity and prevalence, depending on the underlying cause.
In the case of peripheral hypotonia, the patient has a variable degree of impairment in the ability to move the extremities against gravity. The infant is usually alert, has a normal sleep-wake pattern, and responds to the surroundings appropriately. There is usually no cognitive impairment; however, gross and fine motor skills might be delayed. The reflexes are usually reduced or absent. Patients often have feeding difficulties, respiratory impairment, along with impaired ocular and facial movements.
In a hypotonic newborn, it is essential to proceed systematically to reach a correct diagnosis. The initial assessment is aimed at ruling out systemic disorders. Examination for the abnormalities of deep tendon reflexes and laxity of ligaments helps in considering peripheral causes.
If suspected, sepsis must be ruled out with cultures of the blood, urine, and cerebrospinal fluid. Additionally, obtaining a complete blood count and comprehensive metabolic profile, including magnesium and a drug screen. If the neonate is found to have hepatosplenomegaly and/or calcification on a head ultrasound, then a workup for congenital infection should be initiated. It includes toxoplasmosis, rubella, cytomegalovirus, herpes simplex, and human immunodeficiency virus (TORCH) titers, urine CMV studies, and Zika virus testing. For assessment of the central causes of hypotonia, a workup should be done to look for genetic and metabolic disease as a cause. In the presence of dysmorphic features or congenital malformations, a chromosome analysis with routine karyotyping or specific testing for fluorescence in situ hybridization (FISH) can aid in the diagnosis of certain diseases such as Down syndrome and Prader-Willi syndrome.
Metabolic disorder screening is done when there is multisystemic involvement. Screening for carbohydrate and mitochondrial disorders with lactate and pyruvate levels may be done. Altered levels of plasma amino acids and urine organic acids may indicate an underlying amino acid disorder or organic acidemia. Acylcarnitine and total carnitine levels can be obtained for defects in the metabolism of organic acids and fatty acids. More specific testing may be done for peroxisomal disorders with very-long-chain fatty acids and plasmalogens. When suspecting peripheral hypotonia, a creatine kinase (CK) level should be done. CK is typically very elevated (more than 10X normal) in muscular dystrophies.
Electrophysiologic studies can be used as a screening tool for peripheral causes of hypotonia. However, it may be difficult to perform and interpret in a neonate or a young infant. They can differentiate among disorders involving nerves, muscle, or neuromuscular junctions. If CK is mildly elevated (less than 10X normal) and electromyography (EMG) is myopathic, then a muscle biopsy will be needed. Muscle biopsy with immunohistochemical staining and electron microscopy can help differentiate between various muscular dystrophies and myopathies. Although an invasive procedure, it plays an important role in diagnosis and guiding the further workup. If the EMG is neuropathic, then testing for SMA, hereditary sensorimotor neuropathy, and Dejerin-Sottas syndrome should be done.
Decrement or facilitation on EMG would suggest the disease of the neuromuscular junction. Radiologic evaluation with magnetic resonance imaging (MRI) and computed tomography (CT) of the brain can aid in the diagnosis of various causes of central hypotonia. Structural changes, migration defects, brain stem defects (Joubert syndrome), and abnormal signaling defects in the white matter and brain stem can be seen on neuroimaging. Magnetic resonance spectrometry can be useful in diagnosing certain metabolic disorders.
In general, the treatment is supportive and most of the time takes precedence over finding the underlying cause. It is tailored to the symptoms of the infant and may depend on the underlying cause. An interprofessional team approach leads to better outcomes for patients. Rehabilitation, nutritional, and respiratory support must be provided. In cases of central hypotonia other than hypoxic-ischemic encephalopathy, the involvement of a metabolic expert and a geneticist is essential. Occupational, speech, and physical therapy have shown to be beneficial and play a crucial role in maximizing muscle function and also play an important role in preventing secondary anatomic deformities. Nutritional support is very important in these patients as they are often underweight and have various macro/micronutrient deficiencies. Their requirements may increase during illness, and it must be addressed. In severe cases with weakness of chest muscles, nasogastric or percutaneous gastrostomy tubes are needed for nutrition.
Specific treatment can be provided in certain cases such as Pompe disease, where early enzyme replacement therapy can significantly improve the outcome. Recently few treatments have been approved by the US Food and Drug Administration for SMA, although these are among the most expensive treatments available. Spinraza is gene therapy that repairs the SMN2 gene. Zolgensma replaces the missing or defective SMN1 gene. While Spinraza and Zolgensma are given intrathecally, Risdiplam is recently approved as oral therapy.
Genetic counseling must be done for parents. Prenatal testing and testing for at-risk relatives must be offered whenever applicable. Parents must be actively involved from the beginning and should be educated about the disease.
Systemic diseases that tend to affect the entire central nervous system are the most frequent cause of hypotonia in neonates. Congestive heart failure in an infant born with a congenital heart defect is a frequent cause of hypotonia in newborns. Since most of the energy is used in breathing and pumping the blood to the body, the infants have significant hypotonia and weakness. Strength is difficult to assess because of the lack of any voluntary effort by an acutely ill infant. Another common cause is sepsis, which often presents with hypotonia, which can sometimes be severe as well. Newborns who have suffered a hypoxic-ischemic insult present with depressed consciousness in the neonatal period along with hypotonia. As time progresses, the infant gains consciousness and ends up having increased tone and hyperreflexia by the end of 2 to 3 months. Metabolic disorders also present with generalized hypotonia, but these infants commonly have an altered mental status. They may also appear septic, but the diagnosis is only made once the metabolic screen results are available. Genetic/chromosomal causes account for a large number of causes of hypotonia. Numerous genetic syndromes can lead to hypotonia, and it can be difficult for a clinician to identify them without the help of a genetic expert. They present with central hypotonia, dysmorphic features, developmental abnormalities, and positive family history in most cases.
Down syndrome (trisomy 21) is the most common chromosomal cause. Characteristic features include an up-slanting palpebral fissure, flat facial profile, single transverse palmar crease, and poor Moro reflex. Diagnosis can be confirmed with a high-resolution chromosome analysis or fluorescence in situ hybridization (FISH).
Prader-Willi syndrome (PWS) is among the differential diagnosis in the case of unexplained hypotonia in neonates. The majority of cases (65%-75%) are due to a lack of expression of genes inherited paternally on chromosome 15. About one-fourth of cases are due to maternal disomy 15 (when both chromosomes are inherited from the mother, and there is an absence of paternal derived chromosome 15). Very few cases are because of a defect in the genetic imprinting. Patients with PWS have feeding difficulty, hypotonia, and failure to thrive in early infancy. This is replaced by excessive appetite and obesity in late infancy and childhood. Methylation analysis or a FISH can be used to make the diagnosis.
Peroxisomal disorders are a group of disorders that are a result of mutations in any of the 12 PEX genes, most common being the PEX 1 gene. These disorders can fall anywhere along the spectrum of severity. Zellweger syndrome is the most severe form, and infantile Refsum is the least severe form. They are inherited in an autosomal recessive manner. Patients usually present with significant hypotonia and poor feeding in the newborn period. There is involvement of the liver, kidneys, eyes, brain, bones, and adrenals. Diagnosis is based on the levels of very-long-chain fatty acids, with elevated levels of C26 and C26:1. Additionally, there is an elevated ratio of C26/C22 and C24/C22, along with elevation in the plasma levels of pristanic acid and phytanic acid.
Benign congenital hypotonia is a nonprogressive disorder of the neuromuscular system. It is commonly seen and is a diagnosis of exclusion. Muscle tone improves with increasing age, but the patient often has delayed milestone achievement. History and physical examination are not suggestive of a neurologic or a metabolic cause. Routine blood tests, including muscle enzyme results, are normal. It is associated with the risk of joint dislocations later in life, and parents must be counseled about it.
Pompe disease (PD), a rare autosomal recessive disease, is caused by the deficiency of acid alpha-glucosidase deficiency. There is an accumulation of glycogen in the lysosomes in the heart and the skeletal muscle tissue. It can present as the classic infantile PD, which has less than 1% enzyme activity. It is seen in the neonatal period with marked hypotonia, failure to thrive, hepatomegaly, and often leads to death within the first year of life due to cardiac or respiratory causes if untreated. The electrocardiogram shows a short P-R interval and a wide QRS complex, which is a characteristic finding. A definitive diagnosis is made by a muscle biopsy, which shows a lower acid maltase enzyme activity. Enzyme replacement therapy is an approved treatment for infantile PD. Earlier treatment initiation has been associated with better outcomes.
Peripheral hypotonia - Motor nerves, neuromuscular, drug toxicity, or muscular pathology:
A. Motor neuron disease
Spinal muscular atrophy (SMA) is an autosomal recessive disease that involves the anterior horn cells in the spinal cord and motor nuclei of the brainstem. It is a progressive neuromuscular degenerative disorder that results in proximal muscle weakness and paralysis. There are 4 main types of SMA (SMA 1, SMA 2, SMA 3, and SMA 4), which are based on the age at which the disease presents (from pre/perinatal to adulthood) and the maximum motor function achieved. Clinical features include symmetric proximal muscle weakness, atrophy, tongue fasciculations, and decreased to absent reflexes. These patients are also at increased risk of aspirations and failure to thrive. The weakness usually progresses to respiratory insufficiency and eventually, death. Patients have normal cognition regardless of the type.
B. Neuromuscular junction abnormalities include myasthenic syndromes and botulism
Congenital myasthenic syndromes are due to the mutations in genes that are responsible for the structure and function of the neuromuscular junction. The gene mutation results in impaired neuromuscular transmission. Most of them are inherited in an autosomal recessive manner. It can present shortly after birth to early childhood, and rarely by adulthood. The ocular, bulbar, and limb muscles are involved with the sparing of cardiac and smooth muscles. Characteristic features include hypotonia, feeding difficulties, expressionless face, progressively weakening cry, ptosis, and respiratory problems that may progress to cyanosis and apnea. Diagnosis is usually made with EMG showing abnormal compound action potential with repetitive low-frequency stimulation. The patient's response to subcutaneous or intravenous injection of edrophonium chloride can also be used for diagnosis.
The transient acquired myasthenic syndrome is seen in neonates born to mothers with myasthenia gravis. There are antibodies against the acetylcholine receptors in the mother, which passively transfer the placenta and interfere with the neuromuscular transmission in the neonate. Symptoms are seen within 2 to 3 days of life and resolve within 2-4 weeks with complete recovery. The amount of antibody transferred across the placenta directly correlates with the severity of the symptoms. Symptoms include feeding difficulties, hypotonia, swallowing, and sucking difficulties, and they usually have a weak cry with an expressionless face. There may or may not be respiratory insufficiency. Treatment is symptomatic, which may include exchange transfusion, respiratory support as needed, and intravenous immunoglobulin (IVIg).
Infantile botulism is caused by Clostridium botulinum, which is an anaerobic, gram-positive bacteria. The spores are present in the soil and are also present in honey. Ingestion of spores leads to colonization of bacteria in the gut and leads to the release of a potent neurotoxin. The toxin produced is absorbed from the intestines. It acts on the presynaptic receptors, and the release of acetylcholine is inhibited. In foodborne botulism, there is ingestion of the preformed toxin, whereas, in infantile botulism, the toxin is produced in the gut. There is a continuous production of the toxin in infantile botulism as there is bacterial colonization of the large intestine. The affected age group is usually younger than 1 year, with a peak incidence at about 3 months. More severe symptoms are noticed in infants younger than 2 months of age. The first symptom to present is often constipation. Other characteristic features include cranial nerve involvement, respiratory problems, hypotonia, feeding difficulties, and decreased reflexes. The weakness appears to progress in a descending fashion. Diagnosis is made by isolating Clostridium botulinum bacteria itself or the botulinum neurotoxin from the stool. The prognosis is relatively good as recovery will be complete, but it takes several months. If proper care is provided, then there is a less than 2% case-fatality rate. Treatment is mostly supportive care with special attention to pulmonary hygiene and nutritional support. Antibiotics are avoided as they are not known to have any benefit, and they may lead to lysis of bacteria in the intestines resulting in the release of large amounts of toxins.
C. Drug toxicity - magnesium and aminoglycosides
Aminoglycosides provide coverage against gram-negative bacteria and are commonly used in neonates and infants when there is a concern for sepsis and/or meningitis. They are potentially toxic and can cause renal toxicity, ototoxicity, and neuromuscular blockade. Gentamicin has been found to have maximum neuromuscular blocking action. The effects on the neuromuscular junction are greater in the case of preterm neonates due to immature renal function leading to higher levels of the drug in the serum. Clinical features include weakness of muscle and hypotonia. Aminoglycosides must be avoided in patients with neuromuscular junction disorders such as infantile botulism and myasthenia like syndromes.
A magnesium level of more than 1.15 mmol/L (2.8mg/dL) is defined as hypermagnesemia in neonates. It is frequently seen in babies born to mothers who received treatment for eclampsia with magnesium sulfate. Clinical features include hypotonia, hypo/areflexia, respiratory depression, poor feeding, bradycardia, and ileus. The monitoring of the magnesium level and supportive care is often sufficient.
D. Muscle disorders
Congenital muscular dystrophies are inherited disorders. The classification is based on the clinical features in the patients and certain biochemical defects. The presentation can vary from a mild disorder with survival into adulthood to a fatal disease with a poor prognosis. The 2 most common types are:
Congenital myopathies are a group of muscle diseases that are classified based on certain characteristic features. They are present at birth and usually present with hypotonia, feeding problems, delay in milestone achievement, and muscle weakness.
The prognosis depends on the underlying etiology. In some cases, such as transient myasthenia and infantile botulism, there is complete recovery with minimal to no complications. Hypotonia in sepsis or due to other illnesses like CHF also improves once the disease is treated. Certain conditions, such as spinal muscular atrophy and Pompe disease (classic infantile type), can be fatal early in life. Having an interprofessional team approach towards the patient by providing rehabilitation services, nutritional support, home care services, and involving various specialists can alter the prognosis leading to better outcomes.
Complications of hypotonia are usually secondary to the problems associated with it. Mortality is highest under the age of 1 year, and those who survive beyond 1 year age often have developmental delays. The majority of the patients require nutritional support, and they may develop various micro/macro-nutrient deficiencies. Those requiring pulmonary support are more prone to respiratory infections in general and may develop pneumonia frequently. In some diseases, patients who are wheelchair-bound are more prone to fractures, osteopenia, development of contractures, and pressure ulcers even if adequate physical therapy is provided to them.
It is crucial to educate the parents about the disease and its implications. Parents must be actively involved from the beginning in tailoring the treatment options for the patients. The importance of frequent follow-ups should be emphasized to the caregivers. If a patient is on ventilatory support at home, providing basic education about the equipment may prevent unnecessary hospital visits. Making them aware of contraindications, if any, with certain diseases can prevent an irreversible consequence. Active participation and education of the patient's family not only leads to improved outcomes for the patient but is also crucial for the development of a good patient-clinician relationship.
Early recognition of hypotonia and finding the underlying etiology are important for the formulation of an appropriate management plan. Approaching each case systematically by obtaining a detailed history, performing a comprehensive physical examination with a detailed neurological examination, and selecting the investigations carefully, leads to a diagnosis in the majority of the patients of hypotonia. [Level 4] Neuroimaging and DNA based diagnostic tests have been found to successfully reduce the time and expense in reaching a specific diagnosis. [Level 4]
Genetic diseases have moral, ethical, and legal implications. Newborn screening, prenatal testing, and carrier testing should also require the involvement of an ethical team of the institutions. Having an interprofessional team that provides rehabilitation services, respiratory support, nutritional support, and involves various sub-specialists such as geneticists, child neurologists, etc. have been found to have better outcomes for the patient.
|||Sparks SE, Neonatal hypotonia. Clinics in perinatology. 2015 Jun; [PubMed PMID: 26042909]|
|||Kaler J,Hussain A,Patel S,Majhi S, Neuromuscular Junction Disorders and Floppy Infant Syndrome: A Comprehensive Review. Cureus. 2020 Feb 8; [PubMed PMID: 32071826]|
|||Harris SR, Congenital hypotonia: clinical and developmental assessment. Developmental medicine and child neurology. 2008 Dec; [PubMed PMID: 19046184]|
|||Lisi EC,Cohn RD, Genetic evaluation of the pediatric patient with hypotonia: perspective from a hypotonia specialty clinic and review of the literature. Developmental medicine and child neurology. 2011 Jul; [PubMed PMID: 21418198]|
|||Peredo DE,Hannibal MC, The floppy infant: evaluation of hypotonia. Pediatrics in review. 2009 Sep; [PubMed PMID: 19726697]|
|||D'Amico A,Mercuri E,Tiziano FD,Bertini E, Spinal muscular atrophy. Orphanet journal of rare diseases. 2011 Nov 2; [PubMed PMID: 22047105]|
|||Cox N,Hinkle R, Infant botulism. American family physician. 2002 Apr 1; [PubMed PMID: 11996423]|
|||Bodensteiner JB, The evaluation of the hypotonic infant. Seminars in pediatric neurology. 2008 Mar; [PubMed PMID: 18342256]|
|||Kolb SJ,Kissel JT, Spinal Muscular Atrophy. Neurologic clinics. 2015 Nov; [PubMed PMID: 26515624]|
|||Tuysuz B,Kartal N,Erener-Ercan T,Guclu-Geyik F,Vural M,Perk Y,Erçal D,Erginel-Unaltuna N, Prevalence of Prader-Willi syndrome among infants with hypotonia. The Journal of pediatrics. 2014 May; [PubMed PMID: 24582009]|
|||Lee PR,Raymond GV, Child neurology: Zellweger syndrome. Neurology. 2013 May 14; [PubMed PMID: 23671347]|
|||Steinberg SJ,Raymond GV,Braverman NE,Moser AB, Zellweger Spectrum Disorder 1993; [PubMed PMID: 20301621]|
|||Bay LB,Denzler I,Durand C,Eiroa H,Frabasil J,Fainboim A,Maxit C,Schenone A,Spécola N, Infantile-onset Pompe disease: Diagnosis and management. Archivos argentinos de pediatria. 2019 Aug 1; [PubMed PMID: 31339275]|
|||Finsterer J, Congenital myasthenic syndromes. Orphanet journal of rare diseases. 2019 Feb 26; [PubMed PMID: 30808424]|
|||Birdi K,Prasad AN,Prasad C,Chodirker B,Chudley AE, The floppy infant: retrospective analysis of clinical experience (1990-2000) in a tertiary care facility. Journal of child neurology. 2005 Oct; [PubMed PMID: 16417874]|
|||Pasrija D,Tadi P, Congenital Muscular Dystrophy 2020 Jan; [PubMed PMID: 32644382]|
|||Mesquita M,Ratola A,Tiago J,Basto L, Neonatal hypotonia: is it a diagnostic challenge? Revista de neurologia. 2018 Oct 16; [PubMed PMID: 30289151]|